120 related articles for article (PubMed ID: 29956520)
21. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.
Ward AE
Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176
[No Abstract] [Full Text] [Related]
22. [Update on gastroesophageal reflux disease].
Serra Pueyo J
Gastroenterol Hepatol; 2014 Feb; 37(2):73-82. PubMed ID: 24355558
[TBL] [Abstract][Full Text] [Related]
23. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
[TBL] [Abstract][Full Text] [Related]
24. Gaviscon and gastroesophageal reflux in children.
Buts JP; Leclercq V
J Pediatr Gastroenterol Nutr; 1987; 6(3):482-3. PubMed ID: 2828595
[No Abstract] [Full Text] [Related]
25. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
Pouchain D; Bigard MA; Liard F; Childs M; Decaudin A; McVey D
BMC Gastroenterol; 2012 Feb; 12():18. PubMed ID: 22361121
[TBL] [Abstract][Full Text] [Related]
26. [Esophageal reflux and peptic ulcer. An exclusive advanced education service of the Gastro-Liga for family physicians].
Fortschr Med; 1998 Dec; 116(34):35-8. PubMed ID: 10024760
[No Abstract] [Full Text] [Related]
27. Oesophageal disease in the elderly.
Pelemans W; Vantrappen G
Clin Gastroenterol; 1985 Oct; 14(4):635-56. PubMed ID: 2867841
[No Abstract] [Full Text] [Related]
28. Managing childhood gastro-oesophageal reflux.
Drug Ther Bull; 1997 Oct; 35(10):77-80. PubMed ID: 9489057
[No Abstract] [Full Text] [Related]
29. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children.
Forbes D; Hodgson M; Hill R
J Pediatr Gastroenterol Nutr; 1986; 5(4):556-9. PubMed ID: 3016226
[TBL] [Abstract][Full Text] [Related]
30. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
[TBL] [Abstract][Full Text] [Related]
31. Effect of alginate in patients with GERD hiatal hernia matters.
Vardar R; Keskin M; Valitova E; Bayrakci B; Yildirim E; Bor S
Dis Esophagus; 2017 Oct; 30(10):1-7. PubMed ID: 28859383
[TBL] [Abstract][Full Text] [Related]
32. [Multicenter study of sodium alginate in the treatment of regurgitation in infants].
Le Luyer B; Mougenot JF; Mashako L; Chapoy P; Olives JP; Morali A; Chevallier B; Ginies JL; Dupont C; Dagorne M
Ann Pediatr (Paris); 1992 Dec; 39(10):635-40. PubMed ID: 1485782
[TBL] [Abstract][Full Text] [Related]
33. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
[TBL] [Abstract][Full Text] [Related]
34. The suppression of gastro-oesophageal reflux by alginates.
Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
[TBL] [Abstract][Full Text] [Related]
35. [Influence of sodium alginate on the intestinal transit in low birth weight newborn infants].
Chouraqui JP; Morer I; Renard P; Bielsky MC; Richard-Berthe C; Rambaud P
Pediatrie; 1993; 48(6):473-7. PubMed ID: 8247649
[TBL] [Abstract][Full Text] [Related]
36. [Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"].
Lazebnik LB; Bordin DS; Masharova AA; Dzhulaĭ GS; Butov MA; Abdulkhakov RA; Eremina EIu; Tarasova LV; Safonova OV; Firsova LD; Kozhurina TS
Eksp Klin Gastroenterol; 2010; (6):70-6. PubMed ID: 20731169
[TBL] [Abstract][Full Text] [Related]
37. [Gaviscon in reflux symptoms. Results of a drug monitoring study].
Hutt HJ; Tauber O; Flach D
Fortschr Med; 1990 Oct; 108(31):598-600. PubMed ID: 2258131
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of action, efficacy, and onset dynamics of a single dose of alginates in patients with heartburn and GERD].
Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
Eksp Klin Gastroenterol; 2009; (4):77-85. PubMed ID: 19960998
[TBL] [Abstract][Full Text] [Related]
39. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
Tytgat GN; Simoneau G
Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
[TBL] [Abstract][Full Text] [Related]
40. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH.
Del Buono R; Wenzl TG; Ball G; Keady S; Thomson M
Arch Dis Child; 2005 May; 90(5):460-3. PubMed ID: 15851425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
